Steven William Collier

US Patent:

20030165563, Sep 4, 2003

Filed:

Dec 20, 2002

Appl. No.:

10/327459

Inventors:

Brendan Murphy - Mystic CT, US
Steven Collier - Berkeley CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

Assignee:

Pfizer Inc.

International Classification:

A61K031/7052
A61K009/20

US Classification:

424/465000, 514/028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20050013835, Jan 20, 2005

Filed:

Aug 6, 2003

Appl. No.:

10/636013

Inventors:

Steven Collier - Oakland CA, US
William Curatolo - Niantic CT, US
Barbara Johnson - Niantic CT, US
Brendan Murphy - Mystic CT, US

International Classification:

A61K031/7048
A61K009/00
A61K009/14

US Classification:

424400000, 514028000

Abstract:

This invention relates to a powder for oral suspension, and an oral suspension made therefrom, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin. This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by adding a surface tension reducing excipient that reduces the surface tension of the aqueous vehicle. Furthermore, this invention relates to a method for reducing the conversion of a non-dihydrate azithromycin, in an unflavored oral suspension, by raising the viscosity of the oral suspension, and in a flavored oral suspension by lowering the viscosity of the oral suspension.

US Patent:

20050287209, Dec 29, 2005

Filed:

Jul 26, 2005

Appl. No.:

11/190393

Inventors:

Brendan Murphy - Quaker Hill CT, US
Steven Collier - Oakland CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

International Classification:

A61K031/7052
A61K009/20

US Classification:

424464000, 514028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20060024363, Feb 2, 2006

Filed:

Aug 26, 2005

Appl. No.:

11/212332

Inventors:

Brendan Murphy - Mystic CT, US
Steven Collier - Berkeley CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

International Classification:

A61K 9/20
A61K 31/7052

US Classification:

424464000, 514028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20060024364, Feb 2, 2006

Filed:

Aug 26, 2005

Appl. No.:

11/213022

Inventors:

Brendan Murphy - Mystic CT, US
Steven Collier - Berkeley CA, US
Ernest Quan - East Lyme CT, US
Barbara Johnson - Niantic CT, US

International Classification:

A61K 31/7052
A61K 9/20

US Classification:

424464000, 514028000

Abstract:

The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

US Patent:

20130260426, Oct 3, 2013

Filed:

Dec 7, 2011

Appl. No.:

13/992138

Inventors:

Ee Lui Ang - Singapore, SG
Oscar Alvizo - Fremont CA, US
Behnaz Behrouzian - Sunnyvale CA, US
Michael Clay - Menlo Park CA, US
Steven Collier - Lexington MA, US
Ellen Eberhard - Fallbrook CA, US
Fan Jaslyn Fu - Singapore, SG
Shiwei Song - Singapore, SG
Derek Smith - Singapore, SG
Magnus Widegren - Craigavon, GB
Robert Wilson - San Francisco CA, US
Junye Xu - Singapore, SG
Jun Zhu - Chandler AZ, US

International Classification:

C12P 13/02

US Classification:

435122, 435189, 536 232, 4353201, 435129, 435130, 43525411, 4352542, 4352523, 435117, 435125

Abstract:

The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenyl-methyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

US Patent:

20220372452, Nov 24, 2022

Filed:

Jun 6, 2022

Appl. No.:

17/833788

Inventors:

- Redwood City CA, US
Oscar Alvizo - Fremont CA, US
Behnaz Behrouzian - Sunnyvale CA, US
Michael D. Clay - Menlo Park CA, US
Steven J. Collier - Concord MA, US
Ellen D. Eberhard - Fallbrook CA, US
Fu Fan - Singapore, SG
Shiwei Song - Singapore, SG
Derek J. Smith - Singapore, SG
Magnus Widegren - Craigavon, GB
Robert Wilson - Meldreth, GB
Junye Xu - Singapore, SG
Jun Zhu - Chandler AZ, US

International Classification:

C12N 9/02
C12P 11/00
C12P 41/00
C12P 13/02

Abstract:

The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

US Patent:

20210222134, Jul 22, 2021

Filed:

Mar 17, 2021

Appl. No.:

17/204189

Inventors:

- Redwood City CA, US
Oscar Alvizo - Fremont CA, US
Behnaz Behrouzian - Sunnyvale CA, US
Yong Koy Bong - Singapore, SG
Steven J. Collier - Concord MA, US
Anupam Gohel - Bekasi, ID
Jagadeesh Mavinahalli - Maharashtra, IN
Naga K. Modukuru - Singapore, SG
Emily Mundorff - Garden City NY, US
Derek J. Smith - Singapore, SG
Shiwei Song - Singapore, SG
Wan Lin Yeo - Singapore, SG

International Classification:

C12N 9/04
C07K 14/47
C12P 17/10

Abstract:

The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.